Assessing the Benefits of a Painless Lancing Device Among Diabetes Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-04

Study Completion Date

2021-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the benefits of a painless lancing device among diabetes subjects in improving self-monitoring frequency and HbA1c compared to the conventional lancing device.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes

NCT01713348

Diabetes Mellitus

COMPLETED PHASE4

Medtronic 670G Insulin Pump and the Impact on Glycemic Control, Quality of Life, and Compliance

NCT04329871

Type 1 Diabetes Mellitus

UNKNOWN

Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes

NCT06181721

Diabetes Mellitus

COMPLETED NA

SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c

NCT00598663

Diabetes Mellitus, Type 1

COMPLETED NA

Automated Insulin Delivery for INpatients With DysGlycemia (AIDING) Feasibility

NCT04714216

Diabetes Mellitus

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Self-monitoring of glucose forms the cornerstone of diabetes management. There are multiple limiting factors towards efficient self- monitoring of blood glucose, including cost barriers, inconvenience, investment of time, pain associated with pricking etc. Pain has perceived as a major impediment to the self-monitoring of blood glucose.

Genteel lancing device offers a painless pricking experience and hence helps to report blood sugar values at least 4 times a day. The perceived pain sensitivity of the study subjects would be assessed using the 4- point pain screening questionnaire during the course of the study.

The aim of this study is to gather information on the percentage reduction in HbA1c values in diabetes patients as compared to the baseline values after three months and six months respectively brought about by percentage SMBG adherence, defined as the percentage of total recorded SMBG values as compared to the ideal number of readings over the 24-week period. SMBG adherence = actual number of fingerpricks (6 times daily in type 1 subjects or twice weekly in type 2 subjects).

SMBG adherence can be provisionally attained by multiple pricking using painless Genteel lancing device compared to the conventional lancing device. Additionally, the subject is asked about the likelihood they would use the device if available for routine SMBG practice in the future.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Genteel arm

In the Genteel arm, the subjects exclusively use the Genteel device for the first 12 weeks, and then switch to the conventional method of SMBG for an additional 12 weeks. This arm will use Butterfly Touch Lancets (BTL) throughout the study.

Group Type EXPERIMENTAL

Genteel lancing device

Intervention Type DEVICE

Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively

Conventional lancing device

Intervention Type DEVICE

Conventional lancing device

Conventional arm

In the Conventional arm, the subjects use the conventional method of SMBG for the first 12 weeks and then switch to the Genteel device for an additional 12 weeks. This arm will use the lancet and lancing device which they were using prior to randomization to the study.

Group Type ACTIVE_COMPARATOR

Genteel lancing device

Intervention Type DEVICE

Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively

Conventional lancing device

Intervention Type DEVICE

Conventional lancing device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genteel lancing device

Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively

Intervention Type DEVICE

Conventional lancing device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Less than or equal to 70 years of age. If minor (\<18 years), accompanied by caretaker.
2. Diagnosed with either Type 1 or Type 2 diabetes including newly diagnosed. 50% of the study participants will be type 1 diabetes subjects and 50% will be type 2 diabetes subjects
3. Presenting with an uncontrolled glycemic status (HbA1c \>8.0%).
4. Ready for Self-Monitoring of Blood Glucose (SMBG) practices.
5. Attending physician prescribed testing at least 2 times per day
6. Judged by the study trainer to be competent to correctly use Genteel AND demonstrated to the trainer that the subject can use the Genteel device properly.